ACUMEN PHARMACEUTICALS INC
ABOSNASDAQTrading Snapshot
- Day Range
- $2.26 – $2.50
- 52-Week Range
- $1.50 – $3.60
- Volume (shares)
- 1,405,675
- Avg Volume (shares)
- —
- Shares Outstanding
- 72.3M
- Next Earnings
- 2027-03-24
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 113.5x
- EPS (TTM)
- $-1.63
- Dividend Yield
- —
- Dilution (1yr)
- +0.9%
ACUMEN PHARMACEUTICALS INC
ABOS
StockOtter · stockotter.spaceAbout ACUMEN PHARMACEUTICALS INC
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout
Acumen Pharmaceuticals is rated a speculative Buy ahead of November 2026 Phase 2 ALTITUDE-AD data for sabirnetug in early Alzheimer's disease. I estimate ABOS fair value at $2.57 per share, a 14% premium to market, based
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript
Acumen Pharmaceuticals Q3 Earnings Call Highlights
Acumen Pharmaceuticals NASDAQ: ABOS said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble amyloid-beta oligomers
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in November 2026 IND filing for the Enhanced Brain Delivery™ (EBD®) pro
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble